Predicine to Attend 2022 AACR Conference in New Orleans to Highlight the Launch of PredicineBEACON™, a Novel, Tissue-agnostic, Actionable Assay for Minimal Residual Disease (MRD) Detection and the Recent Publication of Several Studies in Genitourinary (GU) Cancers PredicineBEACON™ offers ultra-sensitive detection of disease recurrence and is compatible with blood, urine- and/or tissue specimens. Urine-based MRD has...

Predicine Expands Its Footprint in the Greater Chicago Area to Better Serve Their Patients by Increasing Daily Capacity and Faster Turnaround Time SCHAUMBURG, Ill., April 11, 2022 /PRNewswire/ — Predicine, a global molecular insights company committed to advancing precision medicine in oncology and infectious diseases, announces the grand opening of its Chicago lab in Schaumburg, IL on April 2, 2022. This lab...